Howard Berman - Jan 3, 2023 Form 4/A - Amendment Insider Report for Coya Therapeutics, Inc. (COYA)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ David Snyder, Attorney-in-Fact
Stock symbol
COYA
Transactions as of
Jan 3, 2023
Transactions value $
$0
Form type
4/A - Amendment
Date filed
1/17/2023, 07:01 PM
Date Of Original Report
Jan 4, 2023
Previous filing
Dec 28, 2022
Next filing
Mar 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding COYA Common Stock, par value $0.0001 per share 939K Jan 3, 2023 By Bertex LLC F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4/A amends the Form 4 filed by the Reporting Person on January 4, 2023 (the "Original Form 4"), which inadvertently reported the incorrect number of securities in column 5 of Table I. This Form 4/A is being filed solely to correct the number of securities reported in column 5 of Table I. No other amendments or changes have been made to the Original Form 4.
F2 Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.